Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

A Survey Among Italian Physicians During COVID-19 Outbreak. Could Bacillus Calmette–Guérin Vaccine Be Effective Against SARS-CoV2?

Tytuł:
A Survey Among Italian Physicians During COVID-19 Outbreak. Could Bacillus Calmette–Guérin Vaccine Be Effective Against SARS-CoV2?
Autorzy:
Vincenzo Patella
Alessandro Sanduzzi
Dario Bruzzese
Giovanni Florio
Raffaele Brancaccio
Gabriella Fabbrocini
Gabriele Delfino
Temat:
SARS-CoV2
COVID-19
trained immunity
natural killer cells
innate immunity
epidemiology
Therapeutics. Pharmacology
RM1-950
Źródło:
Frontiers in Pharmacology, Vol 12 (2021)
Wydawca:
Frontiers Media S.A., 2021.
Rok publikacji:
2021
Kolekcja:
LCC:Therapeutics. Pharmacology
Typ dokumentu:
article
Opis pliku:
electronic resource
Język:
English
ISSN:
1663-9812
Relacje:
https://www.frontiersin.org/articles/10.3389/fphar.2021.646570/full; https://doaj.org/toc/1663-9812
DOI:
10.3389/fphar.2021.646570
Dostęp URL:
https://doaj.org/article/276eaf1cfc1b4af8a6a9927536ae4a5c  Link otwiera się w nowym oknie
Numer akcesji:
edsdoj.276eaf1cfc1b4af8a6a9927536ae4a5c
Czasopismo naukowe
Background: Epidemiological studies show that BCG-vaccinated population seems to be more likely protected from COVID-19 infection, but WHO gave a stark warning on use of BCG vaccine without confirmed COVID-19 trials. The aim of the study is to evaluate whether TB vaccination, performed several years earlier, could confer protection against COVID-19.Methods: After the Ethical Committee authorization, professional orders were used to contact physicians with an online survey. Specialty, COVID-19 infection and previous BCG vaccination were recorded. Statistical data analysis was performed.Results: 1906 physicians answered the questionnaire, (M = 1068; F = 838; mean age 50.7 ± 13.3 years; range 24–87), more than half (1062; 55.7%) experienced BCG vaccination. Professional activity was recorded, and only 49 subjects (2.6%) of them were infected by SARS-CoV2. Among the group of infected people, asymptomatic form occurred in 12 subjects (24.5%); a pauci-symptomatic form in 24 subjects (49.0%); and a severe form (pneumonia and/or respiratory distress) in 13 (26.5%). Considering only the clinically relevant form of COVID-19, period prevalence was 2.2% (23/1062) in the vaccinated group and 1.7% (14/844) in the unvaccinated group (OR: 1.31, 95% C.I.: 0.68–2.63, p = 0.427).Conclusion: Our experience does not confirm the possible protective role of BCG vaccination, performed years earlier, against COVID-19. Although recent epidemiological studies point out in BCG-vaccinated population a lower prevalence of SARS-CoV2 infection, in our cohort of physicians no significant difference was found in terms of prevalence of COVID-19 infection. Our data underline the necessity to follow the WHO warning about the indiscriminate use of BCG vaccine, until clear evidence of protection by BCG vaccination against COVID-19 is fully demonstrated.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies